For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter. The ...

Live Updates Live Coverage Updates appear automatically as they are published. Moderna Still Sickly 9:49 am In further ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

Moderna reduced its 2025 revenue forecast due to deferred UK vaccine deliveries. Despite a smaller-than-expected quarterly loss, its shares fell 7%. The company faces challenges from declining ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Circular RNA may be part of the solution. Because circular RNA has no ends to degrade—unlike linear RNA—the molecule is more stable and its half-life is extended.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...